Pith. sign in

REVIEW

ControllableGPT: A Ground-Up Designed Controllable GPT for Molecule Optimization

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2502.10631 v1 pith:FEM25YDZ submitted 2025-02-15 cs.LG cs.AIq-bio.BM

classification cs.LGcs.AIq-bio.BM
keywords controllablegptmodelsoptimizationcontrollabledruglanguageseq2seqapproach
verification ladder T0 review T1 audit T2 compute T3 formal
0 comments
read the original abstract

Large Language Models (LLMs) employ three popular training approaches: Masked Language Models (MLM), Causal Language Models (CLM), and Sequence-to-Sequence Models (seq2seq). However, each approach has its strengths and limitations, and faces challenges in addressing specific tasks that require controllable and bidirectional generation, such as drug optimization. To address this challenge, inspired by the biological processes of growth and evolution, which involve the expansion, shrinking, and mutation of sequences, we introduce ControllableGPT. This initiative represents the first effort to combine the advantages of MLM, CLM, and seq2seq into a single unified, controllable GPT framework. It enables the precise management of specific locations and ranges within a sequence, allowing for expansion, reduction, or mutation over chosen or random lengths, while maintaining the integrity of any specified positions or subsequences. In this work, we designed ControllableGPT for drug optimization from the ground up, which included proposing the Causally Masked Seq2seq (CMS) objective, developing the training corpus, introducing a novel pre-training approach, and devising a unique generation process. We demonstrate the effectiveness and controllability of ControllableGPT by conducting experiments on drug optimization tasks for both viral and cancer benchmarks, surpassing competing baselines.

Discussion (0). Continue with ORCID to comment.

Pith tools